Weight Loss Drugs GLP-1/GIP Receptor Agonists

Course overview

This live webinar, "Weight Loss Drugs: Clinical Update on GLP-1 and GIP Receptor Agonists" will address the following knowledge gaps for health care professionals. The complexity of obesity. Health professionals know the basics of obesity, such as caloric balance, but need a deeper understanding of its complexity. The webinar explains the multifaceted nature of obesity and its endocrine and metabolic mechanisms. Pharmacological interventions. These treatments are considered when lifestyle changes are not enough. Health care professionals should be informed about the benefits, risks, and eligibility criteria. Special attention is given to vulnerable populations and pregnant patients, since many weight loss drugs are contraindicated. Effectiveness, safety, expected events, and adverse events associated with weight loss drugs. The webinar reviews GLP-1 and GIP drugs and other options including anorexiants, antidepressants, antiepileptics, opioid antagonists, and absorption inhibitors. Gaps in dietetic expertise. Nutritional advice is essential for managing obesity, and health care professionals need updated knowledge based on current research. The webinar also reviews herbal and dietary supplements, including the heavily promoted berberine, sometimes referred to as "natures Ozempic." Mental health connection. The relationship between obesity and mental health is complex and bidirectional. Health professionals need to understand how conditions such as depression, anxiety, and eating disorders can contribute to obesity and how obesity can affect mental health. Pharmacodynamics and drug interactions. GLP-1 receptor agonists delay gastric emptying and may affect the absorption of oral medications. This requires patient assessment for timing changes and dose adjustments. Clinical trials covered include Semaglutide in Obesity STEP 1 to STEP 5 Trials, Liraglutide 3.0 mg in Obesity SCALE Trials, and Tirzepatide for the Treatment of Obesity SURMOUNT 1 Trial. The webinar reviews effectiveness, long term outcomes, adverse events, and warnings. It includes emphasis on vulnerable patients such as those in long term care, individuals with severe obesity BMI over 40, and those with comorbidities.